Tiltbio secures $26 million to advance ovarian cancer drug into Phase II
Finnish biotech Tilt Biotherapeutics has raised $26 million (22.6 million euros) in a series B round to move its lead cancer immunotherapy into mid-stage trials for ovarian cancer, and to fund additional early-stage studies in melanoma and other indications.
The funding will allow the Helsinki-based company to start a Phase II trial of its oncolytic virus candidate, TILT-123 (igrelimogene litadenorepvec), in women with platinum-resistant ovarian cancer. The virus is designed to be delivered intravenously alongside T cell–based immunotherapies or checkpoint inhibitors to improve response rates in hard-to-treat tumors.
Tiltbio’s latest round was backed by existing supporters, including the European Innovation Council Fund, Finnish Industry Investment, Stephen Industries Inc Oy and Lifeline Ventures, which also led a previous $24 million raise in 2023. The new investment brings the company’s total funding to more than $79 million to date.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze